Research Update: Positive Chk1 Programme Model ...

(AIM: SAR)   4 March 2011


                              SAREUM HOLDINGS PLC
                                   ("Sareum")

             Research Update: Positive Chk1 Programme Model Studies
Sareum,  the specialist cancer  drug discovery business,  is pleased to announce
positive  results from  pre-clinical in-vivo  efficacy studies  from their joint
research  collaboration with Cancer Research  Technology Limited ("CRT") and The
Institute of Cancer Research ("The ICR").

A  recent  colon  cancer  pre-clinical  model  study  carried  out  by  The  ICR
demonstrates  that the combination of a  collaboration Chk1 inhibitor, dosed via
the   oral   route,   in   combination  with  a  chemotherapeutic,  gemcitabine,
demonstrates a greater than two-fold reduction in cancer growth rate compared to
treatment with the same dose of gemcitabine without the Chk1 inhibitor.

Further   pre-clinical   in-vivo   studies  for  the  programme  show  that  the
collaboration Chk1 inhibitor, dosed alone, can reduce cancer growth in models of
AML  (acute myeloid leukaemia) and  neuroblastoma (a childhood cancer).  Certain
cancers, such as these, are believed to be dependent on Chk1 for survival.

The  joint research collaboration with the  ICR and CTR targets Chk1 (Checkpoint
Kinase  1). Chk1 is  important in  controlling a  cancer cell's  response to DNA
damage, which may be a consequence of the cancer itself, or intentionally caused
by chemotherapy or radiotherapy.

Sareum's CEO, Dr Tim Mitchell, commented:

"These  are exciting advances,  demonstrating efficacy of  our Chk1 compounds in
several cancer models. Studies on additional models are on-going. We believe the
results  from  the  recently  conducted  studies  will significantly enhance the
licencing  package and assist  the collaboration in  selecting the best compound
for development into a clinical trials candidate".

 Sareum Holdings plc

 Tim Mitchell                                      01223 497 700



 Cancer Research Technology Ltd

 Josie Gray / Duty Press Officer   020 7061 8309 / 07050 264 059



 Merchant Securities Limited (Nomad)

 Simon Clements/Bidhi Bhoma                        020 7628 2200



 Hybridan LLP (Broker)

 Claire Noyce                                      020 7947 4350


Notes for editors:

About Sareum Holdings plc
Sareum  is  a  drug  discovery  company,  headquartered in Cambridge UK, that is
focused  on  producing  targeted  small  molecule  therapeutics to address unmet
medical  needs, primarily  in cancer.  Sareum aims  to successfully deliver drug
candidates  for licensing to  pharmaceutical and biotechnology  companies at the
pre-clinical or early clinical trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration
with  The Institute of  Cancer Research and  Cancer Research Technology Limited.
Novel  chemical  compounds  developed  by  the  collaboration have been shown to
increase  the effectiveness  of current  cancer therapeutics  in several in-vivo
cancer models.

SKIL®  (Sareum Kinase Inhibitor  Library) is Sareum's  drug discovery technology
platform  that has so far produced  the Company's Aurora+FLT3, Aurora+ALK VEGFR-
3, FLT3  & TYK2 kinase cancer and  auto-immune disease research programmes. SKIL
can also generate drug research programmes against other kinase targets.

Sareum  Holdings  plc  joined  the  AIM  market  of the London Stock Exchange in
October  2004, trading under  the symbol  SAR.  For  further information, please
visit www.sareum.co.uk

About Cancer Research Technology Ltd

Cancer  Research Technology Limited (CRT) is an oncology-focused development and
commercialisation  company that  realises cancer  patient benefit from publicly-
funded  research worldwide. CRT works  closely with leading international cancer
scientists,  their  institutes  and  funding  bodies  to  protect,  develop  and
commercialise  oncology-related  discoveries.  CRT  is  wholly  owned  by Cancer
Research  UK, the largest  independent funder of  cancer research in the world.
Further information about CRT can be found at www.cancertechnology.com.








This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE

[HUG#1494573]